1 subscribed
Here was that summary along with pitfalls
This is an AWFUL trial used to expand market share of a UBER costly drug Brentuximab and not actually answer the question of whether patients are better off..... In other words, par for the course in 2018
Let's be very clear about this topic: there are lots of stupid & inefficient parts to medical training, (especially scut work & bad work hours, rotating w disinterested attgs, bad teachers, etc.) I can't tackle it all !
First, consider the first FDA approved therapy for advanced or metastatic HCC-> Sorafenib
These drug advisory committees (DAC) are very important
First, test your knowledge: which of the following screening interventions for colorectal cancer have RCTs showing reduction in cause specific (colon ca) death?
First, let's define health care waste
First, the ISCHEMIA trial is clearly ruffling feathers since the primary endpoint was changed. It is a costly 100mi buck FEDERAL funded trial, and it just switched from a bias resistant to a bias prone endpoint 
Quick recap: In Part 1, we covered this provocative paper by Juni & Zwalen in the @AnnalsofIM on the randomized data for mammography. 
First, There are 2 things you need to know. 
Talking points are things we repeat or hear repeated that come to frame the way we think about a topic. 
I think the story of Theranos is particularly insightful because it shows how hype, lack of skeptical or clear thinking, money and hope can lead us to fail to adequately assess medical technologies until too late. Let me take you through the problem as I see it.
